TG Therapeutics/$TGTX
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About TG Therapeutics
TG Therapeutics Inc is a fully integrated, commercial-stage, biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell diseases. The company has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI (ublituximab-xiiy) for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS). In addition, it is developing TG-1701 (BTK inhibitor), Azer-Cel (allogeneic CD19 CAR T), and TG-1801 (anti-CD47/CD19 bispecific mAb) for B-cell disorders, which are under Phase 1 trials. Geographically, the company generates a majority of its revenue selling BRIUMVI in the United States, with the rest coming from sales in other countries.
Ticker
$TGTX
Sector
Primary listing
Industry
Biotechnology
Headquarters
Employees
352
ISIN
US88322Q1085
Website
TG Therapeutics Metrics
BasicAdvanced
$5.5B
159.36
$0.24
2.21
-
Price and volume
Market cap
$5.5B
Beta
2.21
52-week high
$46.48
52-week low
$16.65
Average daily volume
1.7M
Financial strength
Current ratio
4.023
Quick ratio
2.911
Long term debt to equity
106.45
Total debt to equity
107.288
Interest coverage (TTM)
2.10%
Profitability
EBITDA (TTM)
59.877
Gross margin (TTM)
87.43%
Net profit margin (TTM)
10.13%
Operating margin (TTM)
15.48%
Effective tax rate (TTM)
6.21%
Revenue per employee (TTM)
$1,100,000
Management effectiveness
Return on assets (TTM)
7.26%
Return on equity (TTM)
19.70%
Valuation
Price to earnings (TTM)
159.361
Price to revenue (TTM)
14.284
Price to book
23.23
Price to tangible book (TTM)
23.23
Price to free cash flow (TTM)
-90.339
Free cash flow yield (TTM)
-1.11%
Free cash flow per share (TTM)
-42.01%
Growth
Revenue change (TTM)
33.54%
Earnings per share change (TTM)
-14.74%
3-year revenue growth (CAGR)
265.52%
10-year revenue growth (CAGR)
118.98%
3-year earnings per share growth (CAGR)
-54.07%
10-year earnings per share growth (CAGR)
-17.87%
What the Analysts think about TG Therapeutics
Analyst ratings (Buy, Hold, Sell) for TG Therapeutics stock.
Bulls say / Bears say
TG Therapeutics reported a significant increase in Q4 2024 revenue, reaching $108.2 million, more than doubling the previous year's figure, primarily due to robust sales of BRIUMVI. (Nasdaq)
The company has projected ambitious 2025 targets, including total global revenue of approximately $540 million, with BRIUMVI U.S. net product revenue expected to reach $525 million. (StockTitan)
Analysts have raised their price targets for TG Therapeutics, with B. Riley increasing from $38 to $53, maintaining a positive outlook with a buy recommendation. (Timothy Sykes)
StockNews.com downgraded TG Therapeutics to a 'Sell' rating, indicating potential concerns about the company's future performance. (MarketBeat)
Director Sagar Lonial sold 5,000 shares of TG Therapeutics stock, which could be perceived as a lack of confidence in the company's future prospects. (ETF Daily News)
Cantor Fitzgerald noted that September sales for BRIUMVI needed to be strong to meet consensus estimates, suggesting potential challenges in achieving projected sales figures. (Seeking Alpha)
Data summarised monthly by Lightyear AI. Last updated on 10 Jun 2025.
TG Therapeutics Financial Performance
Revenues and expenses
TG Therapeutics Earnings Performance
Company profitability
TG Therapeutics News
AllArticlesVideos
TG Therapeutics to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference
GlobeNewsWire·3 weeks ago
TG Therapeutics Announces Schedule of Data Presentations for BRIUMVI® in Multiple Sclerosis at the 2025 Consortium of Multiple Sclerosis Centers Annual Meeting
GlobeNewsWire·1 month ago
TG Therapeutics Falls Short On Earnings, But Briumvi Sales Steal the Show
Benzinga·2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for TG Therapeutics stock?
TG Therapeutics (TGTX) has a market cap of $5.5B as of June 27, 2025.
What is the P/E ratio for TG Therapeutics stock?
The price to earnings (P/E) ratio for TG Therapeutics (TGTX) stock is 159.36 as of June 27, 2025.
Does TG Therapeutics stock pay dividends?
No, TG Therapeutics (TGTX) stock does not pay dividends to its shareholders as of June 27, 2025.
When is the next TG Therapeutics dividend payment date?
TG Therapeutics (TGTX) stock does not pay dividends to its shareholders.
What is the beta indicator for TG Therapeutics?
TG Therapeutics (TGTX) has a beta rating of 2.21. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.